PETACH TIKVA, Israel, October 14, 2014 /PRNewswire/ --
OrSense Ltd., developer of solutions for non-invasive measurements of hemoglobin, today announced that CSL Plasma, Germany, has completed the transition to OrSense’s NBM200 Hb testing device for screening of Hb levels in plasma donors.
CSL Plasma is one of the world’s largest plasma collection organizations, operating collection centers across the United States and Germany.
Deployment of the NBM200 systems in all collection centers in Germany started earlier this summer after a thorough evaluation and has now been completed.
Historically, Hb measurement required collection of blood samples, rendering the testing procedures invasive, painful, time consuming and labor intensive. OrSense’s NBM200 offers a non-invasive solution for accurate Hb measurements that eliminates pain, reduces infection risk and enables swift Hb level analysis. The NBM200 solution is also environmentally friendly, as it requires no consumables such as lancets, gloves etc., and no need for hazardous waste handling.
Commented Yoav Reisman, CEO of Orsense: “We are happy and proud of CSL’s selection of the NBM200. CSL was looking to improve donors’ experience and streamline operations and the NBM200 provided both. The NBM200 is the most common Non invasive Hb screening product in blood banks today, in use by dozens of operators around the world and this entry into the world of international plasma collection organizations is a natural expansion”.
About OrSense OrSense is a medical device company developing and marketing non-invasive monitoring systems for measurement of Hemoglobin, based on its proprietary Occlusion Spectroscopy technology. OrSense’s systems are available and been successfully installed in dozens of blood donation facilities worldwide. For additional information, please visit OrSense’s website at http://www.orsense.com.
About OrSense’s Technology
OrSense’s NBM200 is based on the company’s proprietary SpectOLight[TM] technology, which uses an optical measurement platform combined with a ring-shaped sensor that is fitted on the subject’s finger. A gentle pressure is applied by the sensor, temporarily occluding the blood flow in the finger. New blood dynamics are created, generating a unique, strong optical transmission signal, with a high signal-to-noise ratio which is wholly blood specific. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This method, called Occlusion Spectroscopy, provides a quick, accurate and painless measurement of the subject’s blood constituents.
Orsense Ltd. contact:
Mikael Flensburg
Chief Commercial Officer
OrSense Ltd.
Mobile: +46(0)760-477090
E-mail: mikael.flensburg@orsense.com
Help employers find you! Check out all the jobs and post your resume.
